V. Viprakasit

发表

A Regulatory SNP Causes a Human Genetic Disease by Creating a New Transcriptional Promoter

Vip Viprakasit, Jan-Fang Cheng, Edward M. Rubin, 2006, Science.

Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia

J. Dukart, M. Cappellini, C. Brugnara, 2021, British journal of haematology.

An Automated Segmentation of R2* Iron-Overloaded Liver Images Using a Fuzzy C-Mean Clustering Scheme

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2018, Journal of computer assisted tomography.

A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E

Yusuke Nakamura, Vip Viprakasit, Naoyuki Kamatani, 2009, Human Genetics.

Rapid flow cytometric test using eosin-5-maleimide for diagnosis of red blood cell membrane disorders.

V. Viprakasit, K. Tachavanich, V. Tanphaichitr, 2009, The Southeast Asian journal of tropical medicine and public health.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.

Estimating the burden of α-thalassaemia in Thailand using a comprehensive prevalence database for Southeast Asia

S. Bhatt, Sunetra Gupta, F. Piel, 2018, bioRxiv.

A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?

M. Cappellini, V. Viprakasit, A. Taher, 2018, Blood reviews.

Hb G-MAKASSAR [β6(A3)Glu→Ala; CODON 6 (G A G→G C G)]: MOLECULAR CHARACTERIZATION, CLINICAL, AND HEMATOLOGICAL EFFECTS

V. Viprakasit, A. Wiriyasateinkul, B. Sattayasevana, 2002, Hemoglobin.

Recurrent A353V mutation in a Thai family with X-linked dyskeratosis congenita.

V. Viprakasit, V. Tanphaichitr, 2001, Haematologica.

Mutations in the general transcription factor TFIIH result in beta-thalassaemia in individuals with trichothiodystrophy.

J. Tolmie, R. Winter, D. Higgs, 2001, Human molecular genetics.

Serum ferritin values between 300 and 800 ng/mL in nontransfusion‐dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable

M. Cappellini, V. Viprakasit, G. Graziadei, 2017, American journal of hematology.

A Normal Reference of Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry in Healthy Thai Children and Adolescents Aged 5–18 Years: A New Reference for Southeast Asian Populations

J. Pooliam, V. Viprakasit, K. Chokephaibulkit, 2014, PloS one.

An overview of current treatment strategies for β-thalassemia

M. Cappellini, V. Viprakasit, A. Taher, 2014 .

Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox

S. Ha, Chi-kong Li, V. Viprakasit, 2011, International journal of hematology.

Paper-based microchip electrophoresis for point-of-care hemoglobin testing.

Umut A. Gurkan, U. Gurkan, V. Viprakasit, 2020, The Analyst.

Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)

M. Cappellini, V. Viprakasit, A. Taher, 2014 .

Global Globin Network Consensus Paper: Classification and Stratified Roadmaps for Improved Thalassaemia Care and Prevention in 32 Countries

J. Elion, B. Zilfalil, S. Fucharoen, 2022, Journal of personalized medicine.

Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2017, Blood cells, molecules & diseases.

Deferiprone for transfusional iron overload and its roles in developing countries

S. Srichairatanakool, V. Viprakasit, S. Rodmai, 2014 .

Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

M. Cappellini, V. Viprakasit, A. Taher, 2013, Blood transfusion = Trasfusione del sangue.

Deferiprone (GPO‐L‐ONE®) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand

Prapat Suriyaphol, A. Chuansumrit, J. Pooliam, 2013, American journal of hematology.

Intersite validations of the pixel-wise method for liver R2* analysis in transfusion-dependent thalassemia patients: a more accessible and affordable diagnostic technology.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2012, Hematology/Oncology and Stem Cell Therapy.

Children with hemoglobin E/β‐thalassemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: A study from thailand

V. Viprakasit, Pairunyar Nakavachara, 2013, Pediatric blood & cancer.

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

D. Pennell, M. Cappellini, Chi-kong Li, 2012, Haematologica.

Bone mineral density in primarily preadolescent children with hemoglobin E/β‐thalassemia with different severities and transfusion requirements

J. Pooliam, V. Viprakasit, Praewvarin Weerakulwattana, 2022, Pediatric blood & cancer.

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

M. Cappellini, V. Viprakasit, A. Taher, 2016, Drug design, development and therapy.

Hydroxyurea for reducing blood transfusion in non-transfusion dependent beta thalassaemias.

V. Viprakasit, J. Ho, W. C. Foong, 2016, The Cochrane database of systematic reviews.

Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT)

E. Vichinsky, M. Cappellini, V. Viprakasit, 2013 .

Prevalence and distribution of iron overload in patients with transfusion‐dependent anemias differs across geographic regions: results from the CORDELIA study

D. Pennell, V. Viprakasit, A. Piga, 2015, European journal of haematology.

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.

S. Perrotta, M. Cappellini, V. Viprakasit, 2015, Blood.

Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach

M. Telen, V. Viprakasit, B. Kaiser, 2021, BMC Public Health.

Early development of decreased β‐cell insulin secretion in children and adolescents with hemoglobin H disease and its relationship with levels of anemia

J. Pooliam, V. Viprakasit, Pairunyar Nakavachara, 2019, Pediatric blood & cancer.

Baseline levels of plasma endothelin‐1 (ET‐1) and changes during transfusion in thalassemic patients

V. Viprakasit, P. Akarasereenont, K. Durongpisitkul, 2002, American journal of hematology.

Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common α-thalassemia point mutations and deletions

C. Farra, V. Viprakasit, H. Najmabadi, 2007, Clinical chemistry and laboratory medicine.

Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies

M. Cappellini, V. Viprakasit, A. Taher, 2021, Expert review of hematology.

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

E. Neufeld, S. Perrotta, M. Cappellini, 2020, The New England journal of medicine.

Changing patterns in the epidemiology of β‐thalassemia

V. Viprakasit, G. Forni, A. Kattamis, 2020, European journal of haematology.

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)

C. Gwaltney, M. Cappellini, X. Hu, 2018, American journal of hematology.

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO©)

C. Gwaltney, M. Cappellini, V. Viprakasit, 2018, American journal of hematology.

When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia

V. Viprakasit, A. Taher, A. Radwan, 2014, Vox sanguinis.

Variable genotype-phenotype correlations in patients with a rare nondeletional α-thalassemia; Hb Pak Num Po (HBA1: c.396_397insT).

V. Viprakasit, K. Sanpakit, 2014, Journal of pediatric hematology/oncology.

Chapter 23 - Metal antagonists

V. Viprakasit, Worapant Kriengsoontornkij, 2014 .

Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia.

M. Weiss, D. Higgs, V. Viprakasit, 2004, Blood.

The genetic basis of asymptomatic codon 8 frame‐shift (HBB:c25_26delAA) β0‐thalassaemia homozygotes

V. Viprakasit, N. Akar, N. Al-Allawi, 2016, British journal of haematology.

Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2019, BMC Cardiovascular Disorders.

Diagnostic applications of newborn screening for α-thalassaemias, haemoglobins E and H disorders using isoelectric focusing on dry blood spots

V. Viprakasit, S. Chamnanvanakij, Punyanuch Jindatanmanusan, 2014, Annals of clinical biochemistry.

Prevalence of low bone mass among adolescents with nontransfusion‐dependent hemoglobin E/β‐thalassemia and its relationship with anemia severity

J. Pooliam, S. Srichairatanakool, V. Viprakasit, 2018, Pediatric blood & cancer.

In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.

V. Viprakasit, K. Robson, A. Townsend, 2005, Blood.

Hb H disease: clinical course and disease modifiers.

S. Fucharoen, V. Viprakasit, 2009, Hematology. American Society of Hematology. Education Program.

Deletion of the α-globin gene cluster as a cause of acquired α-thalassemia in myelodysplastic syndrome

D. Higgs, D. Steensma, V. Viprakasit, 2004 .

Human primary erythroid cells as a more sensitive alternative in vitro hematological model for nanotoxicity studies: Toxicological effects of silver nanoparticles.

Rawiwan Maniratanachote, V. Viprakasit, Suwimon Boonrungsiman, 2015, Toxicology in vitro : an international journal published in association with BIBRA.

Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin.

V. Viprakasit, K. Robson, A. Townsend, 2005, Blood.

Molecular diagnosis of the first ferroportin mutation (C326Y) in the far east causing a dominant form of inherited iron overload

S. Srichairatanakool, V. Viprakasit, K. Robson, 2004 .

A novel deletion causing alpha thalassemia clarifies the importance of the major human alpha globin regulatory element.

D. Higgs, V. Viprakasit, H. Ayyub, 2006, Blood.

Hemoglobin H disease induced by the common SEA deletion and the rare hemoglobin Quong Sze in a Thai female: longitudinal clinical course, molecular characterization, and development of a PCR/RFLP-based detection method

V. Viprakasit, T. Sura, P. Vathesatogkit, 2007, Annals of Hematology.

Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of α thalassaemia (‐‐MED/αTSaudiα)

D. Higgs, V. Viprakasit, H. Ayyub, 2002, British journal of haematology.

Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development

M. Cappellini, V. Viprakasit, T. Coates, 2021, Expert review of hematology.

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions

M. Cappellini, V. Viprakasit, A. Taher, 2016, British journal of haematology.

A prospective analysis for prevalence of complications in Thai nontransfusion‐dependent Hb E/β‐thalassemia and α‐thalassemia (Hb H disease)

V. Viprakasit, N. Siritanaratkul, S. Ekwattanakit, 2018, American journal of hematology.

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study.

M. Cappellini, V. Viprakasit, A. Taher, 2016, Blood cells, molecules & diseases.

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition

V. Viprakasit, A. Taher, S. Rodmai, 2014, Orphanet Journal of Rare Diseases.

Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment

M. Cappellini, V. Viprakasit, Mohsen Saleh Elalfy, 2016, European journal of haematology.

Common Single Nucleotide Polymorphism of TMPRSS6, an Iron Regulation Gene, Associated with Variable Red Blood Cell Indices in Deletional α-Globin Genotypes

V. Viprakasit, Thidarat Suksangpleng, W. Glomglao, 2022, Genes.

Justification of Universal Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia

V. Viprakasit, P. Surapolchai, Phakatip Sinlapamongkolkul, 2020 .

Hemochromatosis gene (HFE) mutations in South East Asia: a potential for iron overload.

Jennifer J. Pointon, T. Hien, V. Viprakasit, 2003, Blood cells, molecules & diseases.

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

E. Neufeld, S. Perrotta, M. Cappellini, 2018, Blood.

Current approach to iron chelation in children

V. Viprakasit, A. Kattamis, Y. Aydinok, 2014, British journal of haematology.

Clinical Presentation and Molecular Identification of Four Uncommon Alpha Globin Variants in Thailand

V. Viprakasit, K. Tachavanich, S. Ekwattanakit, 2013, Acta Haematologica.

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

D. Pennell, M. Cappellini, Chi-kong Li, 2011, Haematologica.

major human alpha globin regulatory element thalassemia clarifies the importance of the α A novel deletion causing

D. Higgs, V. Viprakasit, H. Ayyub, 2012 .

Assessment of Cardiac Iron Overload in Thalassemia With MRI on 3.0-T: High-Field T1, T2, and T2* Quantitative Parametric Mapping in Comparison to T2* on 1.5-T.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2019, JACC. Cardiovascular imaging.

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion‐dependent thalassemia: An algorithm to guide clinical use when availability is limited

A. Ajlan, V. Viprakasit, A. Taher, 2018, American journal of hematology.

Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.

S. Perrotta, M. Cappellini, V. Viprakasit, 2022, The Lancet. Haematology.

The origin of sickle cell disease in Thailand

V. Viprakasit, K. Tachavanich, S. Ekwattanakit, 2018, International journal of laboratory hematology.

Haemoglobin Ethalassaemia in Sri Lanka

D. Weatherall, N. Olivieri, V. Viprakasit, 2005 .

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm

S. Sheth, M. Cappellini, V. Viprakasit, 2022, HemaSphere.

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia.

M. Cappellini, V. Viprakasit, R. Galanello, 2016, European journal of internal medicine.

Iron chelation therapy in the management of thalassemia: the Asian perspectives

V. Viprakasit, A. Khuhapinant, Kai‐Hsin Lin, 2009, International journal of hematology.

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

M. Cappellini, V. Viprakasit, A. Taher, 2014, European journal of haematology.

GENETIC BASIS, PATHOPHYSIOLOGY AND DIAGNOSIS

S. Fucharoen, V. Viprakasit, R. Origa, 2014 .

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

M. Cappellini, Chi-kong Li, S. Thein, 2010, Haematologica.

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

E. Neufeld, H. Rienhoff, E. Vichinsky, 2011, Haematologica.

A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.

Vip Viprakasit, Hugh Young Rienhoff, Paul Harmatz, 2012, Blood.

FBS0701, a novel oral iron chelator, in transfusional iron overload A phase 2 study of the safety, tolerability and pharmacodynamics of

E. Neufeld, V. Viprakasit, R. Galanello, 2012 .

Treating iron overload in patients with non-transfusion-dependent thalassemia

Vip Viprakasit, Khaled M Musallam, Ali T Taher, 2013, American journal of hematology.

What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1?

P. Horby, M. Hibberd, N. T. Hien, 2010, Epidemiology and Infection.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

M. Cappellini, V. Viprakasit, R. Galanello, 2013, Annals of Hematology.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

ATR-X Syndrome Protein Targets Tandem Repeats and Influences Allele-Specific Expression in a Size-Dependent Manner

Steven J. M. Jones, J. Ragoussis, I. Dunham, 2010, Cell.

Adrenal insufficiency is prevalent in HbE/β‐thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement

V. Viprakasit, Pairunyar Nakavachara, 2013, Clinical endocrinology.

Clinical Classification, Screening and Diagnosis for Thalassemia.

V. Viprakasit, S. Ekwattanakit, 2018, Hematology/oncology clinics of North America.

Revisiting The NTDT vs TDT Classification 10 Years Later.

S. Rivella, M. Cappellini, V. Viprakasit, 2020, American journal of hematology.

Haemoglobin E β thalassaemia in Sri Lanka

TEA Peto, D. Weatherall, V. Viprakasit, 2005, The Lancet.

Mutations in Kruppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression.

S. Philipsen, D. Higgs, V. Viprakasit, 2014, Blood.

Incidence of Ototoxicity in Pediatric Patients with Transfusion-Dependent Thalassemia Who Are Less Well-Chelated by Mono- and Combined Therapy of Iron Chelating Agents

J. Pooliam, V. Viprakasit, V. Tanphaichitr, 2014, Hemoglobin.

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.

V. Viprakasit, F. Galactéros, V. Beynon, 2022, The Lancet. Haematology.

ENDOCRINE AND BONE DISEASE

E. Vichinsky, M. Cappellini, V. Viprakasit, 2013 .

Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.

V. Viprakasit, C. Mahasandana, V. Suvatte, 2001, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusion‐dependent thalassemia

V. Viprakasit, K. Sanpakit, J. Buaboonnam, 2020, Pediatric blood & cancer.

STEM CELL TRANSPLANTATION IN SEVERE THALASSEMIC PATIENTS : WHEN DOES THE CELL NUMBER REALLY MATTER ?

V. Viprakasit, K. Sanpakit, V. Suvatte, 2017 .

Estimating the burden of α-thalassaemia in Thailand using a comprehensive prevalence database for Southeast Asia

S. Bhatt, Sunetra Gupta, F. Piel, 2018, bioRxiv.

The 12.6 kb-deletion in the β-globin gene cluster is the known Thai/Vietnamese (δβ)0-thalassemia commonly found in Southeast Asia

S. Thein, V. Viprakasit, Nipon Chalaow, 2013, Haematologica.

Complex interactions of δβ hybrid haemoglobin (Hb Lepore‐Hollandia) Hb E (β26 G→A) and α+ thalassaemia in a Thai family

V. Viprakasit, V. Tanphaichitr, Kevin D. Clark, 2002, European journal of haematology.

Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand

V. Viprakasit, M. Sirikong, P. Ruangvutilert, 2013, Clinical chemistry and laboratory medicine.

Clinical and hematological phenotype of homozygous hemoglobin E: revisit of a benign condition with hidden reproductive risk.

V. Viprakasit, K. Tachavanich, V. Tanphaichitr, 2009, The Southeast Asian journal of tropical medicine and public health.

Molecular analysis of unknown β-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with β-thalassemias and β-globin variants

V. Viprakasit, P. Yenchitsomanus, V. Tanphaichitr, 2005 .

Identification of Hb Q-India (64 Asp→His) in Thailand

V. Viprakasit, V. Tanphaichitr, W. Chinchang, 2004 .

V. Viprakasit, K. Tachavanich, V. Tanphaichitr, 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Clinical phenotypes and molecular characterization of Hb H-Paksé disease.

D. Higgs, V. Viprakasit, C. Fisher, 2002, Haematologica.

Haemoglobin E beta thalassaemia in Sri Lanka.

D. Weatherall, N. Olivieri, V. Viprakasit, 2005, Lancet.

A Single-Tube Multiplex Gap-Polymerase Chain Reaction for the Detection of Eight β-Globin Gene Cluster Deletions Common in Southeast Asia

V. Viprakasit, P. Giordano, C. Harteveld, 2012, Hemoglobin.

Clinical features and molecular analysis in Thai patients with HbH disease

V. Viprakasit, Thirachit Chotsampancharoen, B. Sattayasevana, 2009, Annals of Hematology.

Association of Xmn I Polymorphism and Hemoglobin E Haplotypes on Postnatal Gamma Globin Gene Expression in Homozygous Hemoglobin E

V. Viprakasit, Y. Monteerarat, K. Tachavanich, 2012, Advances in hematology.

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

V. Viprakasit, S. Sheth, H. Al‐Samkari, 2021, Hematology, Transfusion and Cell Therapy.

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2020 .

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY

M. Cappellini, V. Viprakasit, A. Piga, 2022, HemaSphere.

P1545: DURABILITY OF HEMOGLOBIN RESPONSE AND REDUCTION IN TRANSFUSION BURDEN IS MAINTAINED OVER TIME IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT IN A LONG-TERM EXTENSION STUDY

V. Viprakasit, F. Galactéros, V. Beynon, 2021, HemaSphere.

P1544: BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT

V. Viprakasit, F. Galactéros, H. Al‐Samkari, 2021, HemaSphere.

IRON OVERLOAD AND CHELATION THERAPY

E. Vichinsky, M. Cappellini, V. Viprakasit, 2013 .

Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations: report of four families and literature review

P. Charoenkwan, V. Viprakasit, V. Shotelersuk, 2021, British journal of haematology.

Dinucleotide deletion in –α3.7 allele causes a severe form of α+ thalassaemia

V. Viprakasit, H. Ayyub, A. May, 2003, European journal of haematology.

Homozygous Hemoglobin Tak Causes Symptomatic Secondary Polycythemia in a Thai Boy

V. Viprakasit, K. Sanpakit, G. Veerakul, 2003, Journal of pediatric hematology/oncology.

Common origin of a rare β‐globin initiation codon mutation (ATG→AGG) in Asians

V. Viprakasit, V. Tanphaichitr, W. Chinchang, 2005 .

Co‐inheritance of Hb Pak Num Po, a novel α1 gene mutation, and α0 thalassemia associated with transfusion‐dependent Hb H disease

D. Higgs, V. Viprakasit, G. Veerakul, 2004, American journal of hematology.

De novo deletion within the telomeric region flanking the human α globin locus as a cause of α thalassaemia

J. Hughes, D. Higgs, S. Horsley, 2003, British journal of haematology.

Recent advances in understanding haemochromatosis: a transition state

Jennifer J. Pointon, V. Viprakasit, K. Robson, 2004, Journal of Medical Genetics.

Iron overload in the Asian community.

H. J. de Silva, D. Weatherall, S. Srichairatanakool, 2009, Blood.

Distal renal tubular acidosis associated with anion exchanger 1 mutations in children in Thailand.

V. Viprakasit, P. Yenchitsomanus, D. Wattanasirichaigoon, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Molecular heterogeneity of glucose-6-phosphate dehydrogenase (G6PD) variants in the south of Thailand and identification of a novel variant (G6PD Songklanagarind).

M. Matsuo, V. Viprakasit, K. Nishiyama, 2005, Blood cells, molecules & diseases.

Effect of red blood cell glucose-6-phosphate dehydrogenase deficiency on patients with dengue hemorrhagic fever.

V. Viprakasit, K. Tachavanich, V. Tanphaichitr, 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Identification of the novel signal peptide mutation, antithrombin-Siriraj causes type-I antithrombin deficiency in Thai patients

V. Viprakasit, T. Ruchutrakool, Y. Chinthammitr, 2005, Thrombosis and Haemostasis.

Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.

R. Chapman, Jennifer J. Pointon, V. Viprakasit, 2003, Human molecular genetics.

Early‐onset reduced bone mineral density in patients with pyruvate kinase deficiency

V. Viprakasit, F. Galactéros, John Porter, 2023, American journal of hematology.

α−thalassaemia: a genotype–phenotype correlation and management

V. Viprakasit, 2015 .

Coexistence of juvenile xanthogranuloma and diffuse plane xanthoma in 22-month-old boy could potentially be caused by digenic inheritance of APOB and APOE4 polymorphism

V. Viprakasit, V. Wessagowit, N. Densupsoontorn, 2020 .

Immune‐mediated hemolytic anemia in pediatric renal transplantation

V. Viprakasit, A. Pattaragarn, S. Supavekin, 2006, Pediatric transplantation.

Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder *

V. Viprakasit, P. Yenchitsomanus, K. Tachavanich, 2004, European journal of haematology.

Interaction between Hb E and Hb Yala (HBB:c.129delT); a novel frameshift beta globin gene mutation, resulting in Hemoglobin E/β0 thalassemia

V. Viprakasit, S. Ekwattanakit, Suchada Riolueang, 2018, Hematology.

Phase 2 Clinical Trial Results for Bitopertin, an Oral Glycine Transporter 1 Inhibitor, in Patients with Non-Transfusion Dependent Beta-Thalassemia

J. Dukart, M. Cappellini, S. Nave, 2018, Blood.

Two independent origins of Hb Dhonburi (Neapolis) [beta 126 (H4) Val-->Gly]: an electrophoretically silent hemoglobin variant.

V. Viprakasit, W. Chinchang, Worrawut Chinchang, 2007, Clinica chimica acta; international journal of clinical chemistry.

Clinical Phenotypes and Molecular Diagnosis in a Hitherto Interaction of Hb E / β Thalassemia Syndrome ( β E / β-31 , A → G )

V. Viprakasit, G. Veerakul, V. Tanphaichitr, 2005 .

COMPOUND HETEROZYGOSITY FOR α0-THALASSEMIA (−−THAI) AND Hb CONSTANT SPRING CAUSES SEVERE Hb H DISEASE

V. Viprakasit, V. Tanphaichitr, 2002, Hemoglobin.

Adventitious changes in long-range gene expression caused by polymorphic structural variation and promoter competition

Vip Viprakasit, Chris Fisher, Douglas R Higgs, 2009, Proceedings of the National Academy of Sciences.

Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non‐transfusion‐dependent thalassaemia

M. Cappellini, V. Viprakasit, A. Taher, 2015, British journal of haematology.

Hematological parameters and red blood cell indices in healthy Thai children: a revision for 2005.

V. Viprakasit, G. Veerakul, Wiyakan Utto, 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency

V. Viprakasit, F. Galactéros, M. Morado, 2020 .

Molecular analysis of unknown beta-globin gene mutations using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique and its application in Thai families with beta-thalassemias and beta-globin variants.

V. Viprakasit, P. Yenchitsomanus, V. Tanphaichitr, 2005, Clinical biochemistry.

The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design

D. Pospíšilová, V. Viprakasit, Junlong Li, 2023, BMJ Open.

Genetic association study of tumor necrosis factor-alpha with sepsis and septic shock in Thai pediatric patients.

V. Viprakasit, Suwannee Phumeetham, Nunthawut Chat-Uthai, 2012, Jornal de pediatria.

Hemophagocytic lymphohistiocytosis following dengue hemorrhagic fever in Hb H/Hb Constant Spring patient

V. Viprakasit, K. Sanpakit, K. Chokephaibulkit, 2015, Pediatrics international : official journal of the Japan Pediatric Society.

Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial

M. Cappellini, V. Viprakasit, T. Coates, 2020 .

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia

A. Shields, M. Cappellini, V. Viprakasit, 2023, BMJ open.

Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.

M. Cappellini, V. Viprakasit, A. Taher, 2014, Blood cells, molecules & diseases.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

Deferasirox–Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION)

S. Perrotta, M. Cappellini, V. Viprakasit, 2013 .

Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme

Pairash Saiviroonporn, Vip Viprakasit, Rungroj Krittayaphong, 2015, BMC Medical Imaging.

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

M. Cappellini, V. Viprakasit, R. Galanello, 2012 .

Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study

V. Viprakasit, R. Galanello, A. Taher, 2012 .

Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study

E. Neufeld, H. Rienhoff, E. Vichinsky, 2011 .

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing

V. Viprakasit, K. Sanpakit, J. Buaboonnam, 2021, Mediterranean Journal of Hematology and Infectious Diseases.

An open‐label, multicenter, efficacy, and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia (THETIS): 5‐year results

M. Cappellini, V. Viprakasit, A. Taher, 2022, American journal of hematology.

Osteopenia Is Commonly Present in Prepubertal Children with Severe Hb E/βthalassemia Despite Adequate Transfusion and Iron Chelation Therapy.

V. Viprakasit, P. Kiattisakthavee, L. Weerakulwattana, 2007 .

SERUM FERRITIN FOR PREDICTING CLINICALLY RELEVANT LIC THRESHOLDS TO GUIDE MANAGEMENT OF PATIENTS WITH NONTRANSFUSION-DEPENDENT THALASSEMIA TREATED WITH DEFERASIROX: THALASSA STUDY EXTENSION ANALYSIS

M. Cappellini, V. Viprakasit, R. Galanello, 2013 .

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

M. Cappellini, V. Viprakasit, R. Galanello, 2011 .

E. Neufeld, M. Cappellini, V. Viprakasit, 2020 .

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

S. Perrotta, M. Cappellini, V. Viprakasit, 2019, Blood.

Quality of life in patients with β‐thalassemia: A prospective study of transfusion‐dependent and non‐transfusion‐dependent patients in Greece, Italy, Lebanon, and Thailand

M. Cappellini, V. Viprakasit, A. Taher, 2019, American journal of hematology.

Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later

S. Rivella, M. Cappellini, V. Viprakasit, 2020 .

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

D. Pennell, M. Cappellini, Chi-kong Li, 2010 .

Acute haemolytic crisis in a Thai patient with homozygous haemoglobin Constant Spring (Hb CS/CS): a case report

V. Viprakasit, K. Sanpakit, G. Veerakul, 2004, Annals of tropical paediatrics.

Crushed deferasirox film‐coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single‐arm, interventional phase 4 study (MIMAS)

P. Charoenkwan, V. Viprakasit, M. Izquierdo, 2022, American journal of hematology.

Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassaemia patients real‐world practice: a multicentre study

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2018, British journal of haematology.

Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.

D. Pennell, M. Cappellini, Chi-kong Li, 2009 .

Detection of cardiac iron overload with native magnetic resonance T1 and T2 mapping in patients with thalassemia.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2017, International journal of cardiology.

Comparison of the Region-Based and Pixel-Wise Methods for Cardiac T2* Analysis in 50 Transfusion-Dependent Thai Thalassemia Patients

Vip Viprakasit, Rungroj Krittayaphong, Pairash Saiviroonporn, 2011, Journal of computer assisted tomography.

The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry

A. Baschat, A. Jelin, Jena L. Miller, 2022, Blood advances.

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines

V. Viprakasit, N. Siritanaratkul, A. Khuhapinant, 2021, Scientific Reports.

Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.

M. Cappellini, V. Viprakasit, A. Taher, 2009 .

Using of deferasirox and deferoxamine in refractory iron overload thalassemia

V. Viprakasit, K. Sanpakit, J. Buaboonnam, 2020, Pediatrics international : official journal of the Japan Pediatric Society.

Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.

V. Viprakasit, B. Pongtanakul, 2013, Blood cells, molecules & diseases.

Inter-site validations of the Pixel-Wise method for cardiac T2* analysis in transfusion-dependent Thai thalassemia patients.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Genetic regulation of fetal hemoglobin across global populations

M. Gladwin, K. Ardlie, F. Aguet, 2023, medRxiv.

Dengue hemorrhagic fever in patients with thalassemia.

V. Viprakasit, K. Sanpakit, V. Suvatte, 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

Culture of leukocyte-derived cells from human peripheral blood: Increased expression of pluripotent genes OCT4, NANOG, SOX2, self-renewal gene TERT and plasticity

Jah-yao Liu, V. Viprakasit, Jehng-Kang Wang, 2023, Medicine.

Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand

M. Telen, V. Viprakasit, S. Ekwattanakit, 2021, BMC Public Health.

Natural history of Southeast Asian Ovalocytosis during the first 3 years of life.

V. Viprakasit, Thirachit Chotsampancharoen, V. Laosombat, 2010, Blood cells, molecules & diseases.

INITIATION CODON MUTATION (ATG!A-G) OF THE a2 GENE CAUSES Hb H DISEASE IN THAILAND

V. Viprakasit, V. Tanphaichitr, W. Chinchang, 2005 .

Mutations in the hepcidin gene HAMP and the hemojuvelin gene

Jennifer J. Pointon, V. Viprakasit, K. Robson, 2004 .

International Multi-Site Clinical Validation of Point-of-Care Microchip Electrophoresis Test for Hemoglobin Variant Identification

U. Gurkan, V. Viprakasit, J. Little, 2019, Blood.

Common origin of a rare beta-globin initiation codon mutation (ATG-->AGG) in Asians.

V. Viprakasit, V. Tanphaichitr, W. Chinchang, 2005, Clinical and laboratory haematology.

An automated liver segmentation in liver iron concentration map using fuzzy c-means clustering combined with anatomical landmark data

Vip Viprakasit, Rungroj Krittayaphong, Kittichai Wantanajittikul, 2021, BMC Medical Imaging.

A Novel System for Newborn Screening of Thalassemia and Hemoglobinopathies Using Capillary Electrophoresis Is Superior Than Isoelectric Focusing

J. Pooliam, V. Viprakasit, Suchada Riolueang, 2017 .

Argininosuccinate synthetase deficiency: mutation analysis in 3 Thai patients.

V. Viprakasit, C. Srisomsap, P. Wasant, 2005, The Southeast Asian journal of tropical medicine and public health.

E. Neufeld, M. Cappellini, V. Viprakasit, 2023, European journal of haematology.

Limited Sensitivity of a Rapid SARS-CoV-2 Antigen Detection Assay for Surveillance of Asymptomatic Individuals in Thailand

V. Viprakasit, W. Tulalamba, Jaravee Sukprasert, 2021, The American journal of tropical medicine and hygiene.

Inhibition of H5N1 highly pathogenic influenza virus by suppressing a specific sialyltransferase

V. Viprakasit, P. Auewarakul, O. Suptawiwat, 2010, Archives of Virology.

Co-inheritance of Southeast Asian Ovalocytosis (SAO) and G6PD deficiency associated with acute hemolysis in a Thai patient.

V. Viprakasit, K. Prayongratana, 2019, Blood cells, molecules & diseases.

A Rare Association of α0-Thalassemia (– –SEA) and an Initiation Codon Mutation (ATG→A-G) of the α2 Gene Causes Hb H Disease in Thailand

V. Viprakasit, V. Tanphaichitr, W. Glomglao, 2005 .

Safety and pharmacokinetics of the oral iron chelator SP‐420 in β‐thalassemia

E. Neufeld, V. Viprakasit, A. Taher, 2017, American journal of hematology.

Children with hemoglobin E/β‐thalassemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: A study from thailand

V. Viprakasit, Pairunyar Nakavachara, 2013, Pediatric Blood & Cancer.

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.

D. Pennell, M. Cappellini, Chi-kong Li, 2010, Blood.

A. Chuansumrit, J. Pooliam, S. Srichairatanakool, 2013, American journal of hematology.

Hb H disease: clinical course and disease modifiers.

S. Fucharoen, V. Viprakasit, 2009, Hematology. American Society of Hematology. Education Program.

Further Identification of Hb G-Coushatta [β22(B4)Glu→Ala (GAA→GCA)] in Thailand by the Polymerase Chain Reaction-Single-Strand Conformation Polymorphism Technique and by Amplification Refractory Mutation System-Polymerase Chain Reaction

V. Viprakasit, Worrawut Chinchang, 2007, Hemoglobin.

Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor.

V. Viprakasit, K. Chokephaibulkit, P. Vichyanond, 2008, Asian Pacific journal of allergy and immunology.

Towards an External Quality Assessment for Next Generation Sequencing in the Diagnosis of Rare Inherited Anaemias

D. Swinkels, H. Tamary, A. Iolascon, 2018, Blood.

Αlpha-thalassemia: A practical overview.

V. Viprakasit, H. Al‐Samkari, Thomas D Coates, 2024, Blood reviews.

Incidence of Ototoxicity in Pediatric Patients with Transfusion-Dependent Thalassemia Who Are Less Well-Chelated by Mono- and Combined Therapy of Iron Chelating Agents

J. Pooliam, V. Viprakasit, V. Tanphaichitr, 2014, Hemoglobin.

Current approach to iron chelation in children

V. Viprakasit, A. Kattamis, Y. Aydinok, 2014, British journal of haematology.

Efﬁcacy of deferasirox in reducing and preventing cardiac iron overload in (cid:1) -thalassemia

D. Pennell, M. Cappellini, V. Viprakasit, 2010 .

Efﬁcacy of deferasirox in reducing and preventing cardiac iron overload in (cid:1) -thalassemia

D. Pennell, M. Cappellini, V. Viprakasit, 2010 .

Hb Woodville, a rare α‐globin variant, caused by codon 6 mutation of the α1 gene

V. Viprakasit, Worrawut Chinchang, Pipat Chotimarat, 2006, European journal of haematology.

Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data.

P. Saiviroonporn, R. Krittayaphong, V. Viprakasit, 2017, Blood cells, molecules & diseases.

An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling.

V. Viprakasit, S. Issaragrisil, Methichit Wattanapanitch, 2019, Stem cell research.